Hanmi Pharm's NASH therapy wins tech export award
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
The company said on Monday it will receive the Korea New Drug Development Award for technology export in recognition of its business achievement with efinopegdutide (LAPSGLP/GCG) during the 22nd Korea New Drug Development Award ceremony due on Friday. The event is hosted by Korea Drug Research Association and sponsored by the Ministry of Health and the Welfare and Ministry of Science and ICT.
The Korea Drug Research Association’s new drug development award review committee decided to grant the technology export award to Hanmi Pharma’s NASH treatment based on the technology level, added value, competitiveness, and contribution to national health improvement, according to Hanmi Pharm.
Efinopegdutide was first licensed out to Janssen in 2015, but the Belgium-based pharmaceutical arm of Johnson & Johnson returned all rights after the two disagreed over the drug’s indication although Phase 2 trial data met the primary endpoint of weight loss.
Hanmi Pharm continued to develop the drug by changing the indication after confirming the drug's efficacy in obesity treatment and signed a new out-licensing deal worth $860 million with MSD as a treatment for NASH in August last year.
The deal with MSD is significant as it debunked the widespread industry perception that the return of rights is regarded as a failure in commercial development of novel drugs.
Hanmi Pharm started to develop efinopegdutide in 2010. There is no available cure for NASH which is characterized by complex symptoms due to fatty liver and liver fibrosis.
The multi-target therapy is proven effective against fatty liver, inflammation, and fibrosis, with excellent clinical outcomes in NASH treatment. A Phase 2 clinical trial is expected to begin this year.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Korean shipbuilders win $4.5 bn orders in first two months - Pulse by Maeil Business News Korea
- Hanwha Solutions head Kim Dong-kwan to join satellite venture’s board - Pulse by Maeil Business News Korea
- Renault Samsung CEO warns of output cut from last year’s 17-year low - Pulse by Maeil Business News Korea
- Kakao’s education platform Yanadoo seeks to go public in 2022 - Pulse by Maeil Business News Korea
- Hanmi Pharm’s NASH therapy wins tech export award - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- HBM 경쟁, SK 1라운드 ‘勝’…삼성 2라운드 ‘선빵’ [맞수맞짱]
- ‘김기리 ? 문지인’ 결혼식, 백지영·박진주 ‘축가’...“세기의 결혼식 방불케해”(종합) - MK
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이